PRIMA-1 and APR-246: PRIMA-1 (p53 reactivation with the induction of massive apoptosis) reactivates several p53 mutants through refolding, reduces mutant p53 aggregation in ovarian cancer cells [148], and can sensitize chemotherapy-resistant ovarian cancer cells to cisplatin [149]. This evidence concerns the gene TP53 and ovarian cancer.